Avatrombopag instructions, indications, usage and dosage, side effects

1. Indications

Avatrombopag, commonly known as avatrombopag maleate tablets, is mainly used to treat thrombocytopenia associated with chronic liver disease. This condition is common in patients with chronic liver disease, and thrombocytopenia significantly increases the risk of bleeding when facing surgery or invasive diagnostic procedures. Avatrombopag stimulates the proliferation and differentiation of megakaryocytes in the bone marrow and increases platelet production, thereby reducing the risk of bleeding during surgery or examination and ensuring patient safety. In addition, avatrombopag is also suitable for the treatment of thrombocytopenia and chronic immune thrombocytopenia caused by tumor chemotherapy.

2. Usage and dosage

Usage: Avatrombopag is an oral drug and should be taken with food to increase the bioavailability of the drug. It is recommended to take it at a fixed time every day to ensure the stability of blood concentration.

Dosage: The dosage should be determined based on the patient's baseline platelet count. Specifically, if the platelet count is between 40×10^9/L and less than 50×10^9/L, the recommended dose is 60 mg each time (equivalent to 3 tablets); if the platelet count is less than 40×10^9/L, it is recommended to take 40 mg each time (i.e. 2 tablets). The drug needs to be taken once a day for 5 consecutive days to achieve the desired therapeutic effect.

Special situation handling: If the patient misses a dose while taking the medicine, he should take it immediately after discovery and continue to take it according to the original plan the next day. It should be noted that patients should not increase a single dose to make up for a missed dose to avoid the risk of overdose.

3. Side effects

Avatrombopag may produce some side effects during treatment, and patients need to pay close attention and report to their doctor in a timely manner. Common side effects include:

Fever, abdominal pain, nausea, and headache: These symptoms are usually mild and tolerated by most patients. If symptoms continue to worsen, seek medical attention promptly.

Allergic reactions: A few patients may experience allergic symptoms such as skin itching, redness, swelling, and papules. In severe cases, they may even have difficulty breathing and swallowing. In the event of an allergic reaction, the medication should be stopped immediately and medical attention should be sought.

Hyponatremia: manifested by headache, inability to concentrate, changes in consciousness, etc. Patients should monitor serum sodium levels regularly and supplement if necessary.

Peripheral edema and anemia: These symptoms may be related to the drug's effects on fluid balance and erythropoiesis. If symptoms are obvious, you should consult a doctor promptly.

Thrombus formation/Thromboembolic complications: Avatrombopag may increase the risk of thrombosis, particularly in patients with known risk factors for thromboembolism. Therefore, patients should closely monitor platelet counts and clinical symptoms to detect and deal with thrombotic events promptly.

4. Precautions

Avatrombopag is not indicated for restoring normal platelet counts in patients with chronic liver disease. Pregnant and lactating women should fully assess the risks before use and decide whether to use it under the guidance of a doctor. Safety and effectiveness in pediatric patients have not been established and use in children is not recommended. The safety and effectiveness of medications in elderly patients need to be evaluated based on specific circumstances. Patients should follow the doctor's advice during medication and regularly monitor relevant indicators to ensure the safety and effectiveness of the medication.